Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 3/20 | 0.57 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.57 |
| ▸ | CTSS | P25774 | 9/20 | 0.47 |
| ▸ | CTSL | P07711 | 7/20 | 0.44 |
| ▸ | CTSK | P43235 | 4/20 | 0.44 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.42 |
| ▸ | CCKBR | P32239 | 1/20 | 0.42 |
| ▸ | F11 | P03951 | 2/20 | 0.42 |
| ▸ | PYGL | P06737 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL774953 | 0.86 | GRN (0.64) | GRNSORT1CTSSCTSLCTSK | |
| SCHEMBL777310 | 0.83 | GRN (0.56) | GRNSORT1CTSSCTSLCTSK | |
| SCHEMBL14594658 | 0.79 | GRN (0.61) | GRNSORT1CTSSCTSLCTSK | |
| SCHEMBL3224555 | 0.79 | GRN (0.61) | GRNSORT1CTSSCTSLCTSK | |
| SCHEMBL775068 | 0.78 | GRN (0.62) | GRNSORT1CTSLCCKBR | |
| SCHEMBL3219146 | 0.78 | GRN (0.62) | GRNSORT1CTSLCCKBR | |
| SCHEMBL3218303 | 0.78 | GRN (0.59) | GRNSORT1CTSSCTSLCTSK | |
| SCHEMBL5792757 | 0.77 | GRN (0.56) | GRNSORT1CTSSCTSLCTSK | |
| SCHEMBL775213 | 0.74 | GRN (0.59) | GRNSORT1CTSSGPR132 | |
| SCHEMBL18114408 | 0.74 | GPR132 (0.65) | GRNSORT1CTSSCTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071513-A1 | Compositions and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2012-03-22 | — | — | US | claimed |
| US-20110178087-A1 | Compositions and Their Use as Anti-Tumor Agents | Compass Pharmaceuticals LLC. (US) | 2011-07-21 | — | — | US | claimed |
| US-20090018145-A1 | Compositions and their use as anti-tumor agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-01-15 | — | — | US | claimed |
| EP-1802606-A2 | COMPOSITIONS AND THEIR USE AS ANTI-TUMOR AGENTS | Compass Pharmaceuticals LLC (US) | 2007-07-04 | — | — | EP | claimed |
| WO-2006044975-A2 | COMPOSITIONS AND THEIR USE AS ANTI-TUMOR AGENTS | COMPASS PHARMACEUTICALS LLC (US) | 2006-04-27 | — | — | WO | claimed |
| US-20120071513-A1 | Compositions and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110178087-A1 | Compositions and Their Use as Anti-Tumor Agents | Compass Pharmaceuticals LLC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20090018145-A1 | Compositions and their use as anti-tumor agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071513-A1 | Compositions and Their Use as Anti-Tumor Agents | TP53, VHL, RB1 | GRN 1317/4885SORT1 2868/4885CTSS 1088/4885 |
| US-20110178087-A1 | Compositions and Their Use as Anti-Tumor Agents | TP53, VHL, RB1 | GRN 1317/4885SORT1 2868/4885CTSS 1088/4885 |
| US-20090018145-A1 | Compositions and their use as anti-tumor agents | TP53, VHL, RB1 | GRN 1364/4885SORT1 3091/4885CTSS 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.